Skip to Content

Eli Lilly and Co LLY

Morningstar Rating
$883.88 −2.11 (0.24%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

LLY is trading at a 60% premium.
Price
$883.88
Fair Value
$275.00
Uncertainty
High
1-Star Price
$638.00
5-Star Price
$375.00
Economic Moat
Lvz
Capital Allocation
Cwhlshcp

Bulls Say, Bears Say

Bulls

Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

Bears

The risks to success for Alzheimer’s drug donanemab remain high both in clinical development and insurance coverage.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LLY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$885.99
Day Range
$879.80891.97
52-Week Range
$434.34905.45
Bid/Ask
$884.00 / $899.55
Market Cap
$840.04 Bil
Volume/Avg
3.4 Mil / 2.6 Mil

Key Statistics

Price/Earnings (Normalized)
94.52
Price/Sales
22.22
Dividend Yield (Trailing)
0.55%
Dividend Yield (Forward)
0.59%
Total Yield
0.55%

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
43,000

Competitors

Valuation

Metric
LLY
NVO
MRK
Price/Earnings (Normalized)
94.5249.0260.24
Price/Book Value
65.5744.278.20
Price/Sales
22.2217.915.42
Price/Cash Flow
92.3641.9519.06
Price/Earnings
LLY
NVO
MRK

Financial Strength

Metric
LLY
NVO
MRK
Quick Ratio
0.680.490.68
Current Ratio
1.350.701.25
Interest Coverage
14.1145.823.97
Quick Ratio
LLY
NVO
MRK

Profitability

Metric
LLY
NVO
MRK
Return on Assets (Normalized)
11.20%30.91%5.22%
Return on Equity (Normalized)
57.69%95.22%13.56%
Return on Invested Capital (Normalized)
20.65%73.76%8.29%
Return on Assets
LLY
NVO
MRK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Johnson & Johnson
JNJ
WtdmjkjkrZnpx$358.0 Bil
Merck & Co Inc
MRK
ZcbkvlwMnsy$331.1 Bil
AbbVie Inc
ABBV
CdlmyckqLmvpd$300.9 Bil
AstraZeneca PLC ADR
AZN
PqlqcnzxfPdtg$244.8 Bil
Roche Holding AG ADR
RHHBY
QddjbblvjbFlqf$228.8 Bil
Novartis AG ADR
NVS
NcrxdlpdWsndr$215.1 Bil
Amgen Inc
AMGN
PfkkxygpfbYks$165.3 Bil
Pfizer Inc
PFE
BmykxpzjLxgw$157.2 Bil
Sanofi SA ADR
SNY
XcqbfmlfJwbw$117.4 Bil

Sponsor Center